Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024623 (gastric cancer)
 36,219 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Disease-oriented phase II trials of doxifluridine were performed in advanced colorectal, breast, renal, endometrial, stomach, and ovarian carcinomas. The dose schedule recommended by the phase I trial (12.5 g/m2 by continuous iv infusion over 6 hours once a week for 3 weeks followed by a 1-week rest) was chosen first: the initial dose was later decreased to 10 g/m2 due to the fact that several neurotoxic effects were reported. A total of 207 patients were entered: 137 patients who received at least two courses of treatment were evaluable for response. Therapeutic activity was demonstrated in breast cancer [two complete responses (CR) and 13 partial responses (PR) among 42 patients], colon cancer (seven PRs among 35 patients), and rectal cancer (six PRs among 23 patients). Some therapeutic activity was detected in ovarian cancer (one CR among nine patients), endometrial cancer (one PR among five patients), and stomach cancer (one PR among five patients). No significant activity was noticed in renal cancer (one PR among 18 patients). Nonhematological toxicity was evaluated according to World Health Organization criteria. Nausea and vomiting were recorded in 50% of the patients (Grade 3-4 in 5%), diarrhea was recorded in 20% (Grade 3-4 in 5%), and cutaneous and allergic reactions were recorded in 10% (Grade 3-4 in 2%). Myelotoxicity during the first treatment course was mild; median wbc and platelet count nadirs (x 10(9) cells/L) were 4.1 (range, 0.1-11) and 194 (range, 20-482), respectively. Nevertheless, some cases of acute leukopenia and thrombopenia were reported. Consciousness alterations and neurologic symptoms were the major side effects (72 of 173 evaluable patients), since treatment had to be interrupted in 34 patients and four lethal neurotoxic effects occurred. At the same total dose of doxifluridine, the risk of neurotoxicity significantly increases with age and with the weekly dose and to the contrary it decreases with increasing bilirubin level. Although activity was demonstrated, this treatment cannot be recommended because of major neurotoxicity. Further pharmacological studies seem warranted to define the optimal dosage schedule and to obtain a better therapeutic index.
 ...
PMID:Phase II clinical evaluation of doxifluridine. 294 45

During recent years much evidence has accumulated indicating that diet and nutrition may be important in the aetiology of human cancer. This paper discusses some of the components of diet that have been implicated as both causative and protective agents. Total calorie intake and overnutrition have been associated with breast and uterine cancers, high fat intake with cancer of the breast and large bowel and nitrates with gastric cancer. High fibre intakes are suggested to protect against colo-rectal cancer, and vitamin A, selenium and vitamin E have been inversely associated with various cancers.
 ...
PMID:Food in the aetiology of cancer. 301 55

UFT, a combination antitumor drug consisting of 1 part Futraful and 4 parts Uracil, was administered preoperatively to 10 patients with gastric cancer, 9 patients with colo-rectal cancer and 1 patient with hepatocellular carcinoma. A pharmacokinetic study was then carried out after oral administration of 600 mg per day of UFT, measuring Uracil, Futraful and 5-FU levels in serum and tumor tissue. Preoperative total doses of UFT for gastric cancer were 3.0-11.4 g, for colo-rectal cancer 3.6-16.8 g and for hepatocellular carcinoma 8.4 g. Side effects, mainly gastrointestinal symptoms, were observed in 3 cases. Abnormalities of liver function test, depression of serum protein and bone marrow damage were observed in 4 cases. 5-FU concentration in the tumor tissue was higher than 0.05 mu/g in 15 of 19 patients (79%). This suggested that 5-FU was maintained in the tumor tissue for a longer period. However, it also suggested that the concentration of Uracil in the tumor tissue corresponded to the total dose of UFT as did the degree of side effects.
 ...
PMID:[Effects of preoperative administration of UFT in gastrointestinal cancer]. 308 Sep 66

Analytical epidemiologic studies are less effective when dietary habits are homogenous within a population. For that reason, we performed chronological and spatial correlation analyses between mortality from stomach and large intestinal cancers and various foods/nutrients intakes. The age-adjusted death rates (AADRs) for male colon cancer were strongly associated with the population size and those for female colon cancer and male rectal cancer were weakly associated with the population size, but the AADRs for stomach cancer in both sexes and those for female rectal cancer were not associated. From 1969-71 to 1981-83, the AADRs for stomach and female rectal cancers decreased and the AADRs for colon and male rectal cancers increased. With an increasing population size and from the earlier period to the recent period, the intakes of western-style fat-rich foods such as butter & margarine, cheese and ham & sausage increased and those of rice, fish and some traditional Japanese foods decreased. The results of geographical correlation analyses were generally consistent with the results from the urban-rural variations. The chronological correlation analyses suggested that stomach cancer might be associated with Japanese-style dietary habits after almost no lag time and colon cancer might be associated with westernized dietary habits after a lag time of about 10 years.
 ...
PMID:Per capita foods/nutrients intake and mortality from gastrointestinal cancers in Japan. 311 57

This study was carried out with 48 patients received surgery, i.e., 23 stomach cancer, 8 colon cancer, 6 rectal cancer, 9 breast cancer etc. Patients in group A received UFT in combination with OK-432. Each of UFT or OK-432 was given to the patients in groups B or C, respectively. Changes in the skin reaction to Su-PS were measured before and after dosing, and concentrations of Tegafur and 5-FU in serum and tumor tissues were determined after administration. Analysis of the skin reaction to Su-Ps revealed that patients with positive skin reaction before surgery in group A didn't manifest depression due to sensitization by UFT therapy. Although average values of the skin reaction after dosing were slightly lower compared to those before dosing in group B, sensitization was effective. Values of the skin reaction after dosing were significantly (p less than 0.05) high compared to those before dosing in groups A and C. Concentrations of Tegafur and 5-FU in serum reached to the peak 2 hr later and were maintained high enough to expect clinical responses even at 4 hr after administration in groups A and B. Especially there was not a significant difference between groups A and B in tumor tissue levels of 5-FU, and a high effective concentration was obtained. Combination therapy of UFT with OK-432 exhibited no significant interaction between them in adjuvant immuno-chemotherapy, and satisfactory results were expected in clinical cures.
 ...
PMID:[Study on the preoperative adjuvant therapy of cancer--relation between serum and tumor tissue levels of UFT and OK-432 after administration, and skin reactions to Su-polysaccharide (Su-Ps)]. 312 Jun 45

Colorectal cancer ranks fifth in general cancer morbidity in the Moldavian SSR and second among digestive tumors. Within 1970-1979, the morbidity rate for rectal cancer increased 2.2-fold (from 3.0 to 6.70/0000), cancer of the colon--1.4-fold (from 4.4 to 6.00/0000). Rectal cancer morbidity showed a 4.30/0000 rise in male patients, matched by a 3.20/0000 rise in females. The colonic cancer morbidity rates increased by 1.5 and 1.80/0000, respectively. The results of the analysis of the said indexes suggest that by 1990 the rectal cancer morbidity rate will have reached 8.9 +/- 1.1 and colonic cancer--7.3 +/- 2.40/0000. By 1990, the rate of morbidity for cancer of the large bowel will have surpassed that for stomach cancer and it will rank first among tumors of the digestive tract should the present-day trends of morbidity remain unchanged.
 ...
PMID:[Cancer morbidity of the large intestine and its prognosis in the Moldavian SSR]. 316 Dec 42

This study reports on the taste for salt among patients with gastric, colon, or rectal cancers and among population controls, within the scope of an investigation on those cancers in two Belgian provinces. Among people who systematically added salt to their food, the relative risks observed were as follows: 1.78 for gastric cancer, 1.53 for colon cancer, and 1.74 for rectal cancer. Even though all three were statistically significant, these increases are moderate and may be due to interaction with other, as yet unknown casual factors.
 ...
PMID:Salt and gastrointestinal cancer. 321 61

Adenocarcinomas of the gastrointestinal tract have generally been considered to be radioresistant. In 1974-1975, following an early lead from the Mayo Clinic (Rochester, MN), the Gastrointestinal Tumor Study Group initiated a series of clinical trials of radiation therapy and chemotherapy as surgical adjuvant programs for patients with pancreatic and rectal cancer and for the treatment of locally unresectable gastric and pancreatic adenocarcinomas. The first protocols for pancreatic cancer included a controlled trial of radiation therapy and chemotherapy following pancreatoduodenectomy or total pancreatectomy and also a randomized trial of high-dose radiation therapy, with or without chemotherapy, compared to a lower dose of radiation therapy combined with chemotherapy for patients with locally unresectable tumors. In the treatment of locally incurable gastric cancer, radiation therapy plus chemotherapy was compared to chemotherapy alone, while the rectal trial was a randomized comparison of radiation therapy; chemotherapy; the combination of radiation therapy and chemotherapy; and no further treatment following surgical extirpation. In all cases, the agent used during the course of radiation was 5-fluorouracil. Subsequent trials in pancreatic cancer compared radiation combined with either 5-fluorouracil or doxorubicin and included a pilot study of hyperfractionated radiation therapy combined with 5-fluorouracil. Confirmatory trials were undertaken and are still under analysis in gastric cancer and in rectal cancer. A follow-up trial in pancreatic cancer was developed to establish the importance of the radiation therapy component of combined modality therapy in the treatment of patients with locally unresectable disease. A final study examined the potential for radiation therapy of the liver and systemic chemotherapy in the prevention of metastatic adenocarcinoma of the colon.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:An organized multi-institutional interdisciplinary evaluation of role of radiation therapy alone or combined with chemotherapy in treatment of adenocarcinoma of the gastrointestinal tract. 328 Oct 30

Recent studies identify digestive cancer excesses among workers exposed to cutting fluids, abrasive dusts, and oil smoke. Standardized proportional mortality and mortality odds ratio studies were carried out for a ball bearing plant. Cause of death and work histories were obtained for 702 of 768 hourly employees with ten or more years' service who died between 1969 and 1982. Union and company records were used to define exposure measures. The major findings were significant excesses in proportional mortality ratios (PMR) from stomach cancer (PMR = 2.0) and rectal cancer (PMR = 3.1) among white men. After control for age at death, there was a significant association between stomach cancer and precision grinding exposures, consisting primarily of direct contact with water-based cutting fluids (usually emulsified oils) and their aerosols. Some straight oils and synthetic cutting fluids were used as well. The pattern of stomach cancer is consistent with previous findings and suggests an association with the soluble oil cutting fluids.
 ...
PMID:Causes of death among workers in a bearing manufacturing plant. 337 46

We performed simultaneous measurements of CA 12-5, CEA and Ca 19-9 in the preoperative sera of 87 patients with gastric cancer, 177 patients with colo-rectal cancer and 55 patients with benign diseases. 5.6% of the control patients, 13.8% of the gastric cancer patients and 9.6% of the colo-rectal cancer patients showed Ca 12-5 values of 27.0 U/ml and more. In contrast, the sensitivity of the tumor markers CEA (greater than or equal to 5.0 ng/ml in 17.1% of the gastric cancer and 36.2% of the colo-rectal cancer patients examined) and Ca 19-9 (greater than or equal to 25.0 U/ml in 16.1% of the gastric cancer and 19.8% of the colo-rectal cancer patients) was distinctly higher. The simultaneous determination of three markers on the one hand increased the rate of 'marker-positive' patients (up to 34.5% in gastric cancer and 45.2% in colo-rectal cancer) but on the other hand diminished the specificity (from 96.4% to 89.1%) of the examination.
 ...
PMID:Evaluation of Ca 12-5 as a tumor marker for gastric and colo-rectal cancer in comparison to CEA and Ca 19-9. 347 58


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>